Citius Oncology Successfully Closes $9.0 Million Public Offering
CRANBURY, NJ – July 17, 2025 – Citius Oncology, Inc. (Nasdaq: CTOS), a late-stage biopharmaceutical company focused on developing and commercializing innovative oncology therapies, announced today the successful closing of its previously announced public offering of common stock. The offering resulted in gross proceeds of approximately $9.0 million, before deducting underwriting discounts and commissions and other offering expenses.
The offering consisted of 3,000,000 shares of common stock issued at a price to the public of $3.00 per share. This capital infusion is a significant milestone for Citius Oncology, providing crucial funding to advance its strategic objectives and support its pipeline development efforts.
“We are very pleased with the successful completion of this public offering,” said [Insert Name and Title of Citius Oncology Spokesperson, if available in the original release, otherwise omit or use a general title like “a representative from Citius Oncology”]. “This financing will enable us to further our mission of bringing transformative treatments to patients battling cancer. The support we have received underscores the confidence in our scientific approach and the potential of our lead product candidates.”
The funds raised are expected to be utilized for various key initiatives, including the advancement of clinical trials for Citius Oncology’s promising therapeutic candidates, continued research and development activities, potential regulatory submissions, and general corporate purposes. The company remains committed to its goal of addressing unmet medical needs in the oncology landscape.
[Optional: If the press release mentions specific lead product candidates or target indications, you could add a sentence here like: “The company is particularly focused on advancing its pipeline, which includes [mention lead drug candidate] for the treatment of [mention indication].”]
This successful financing marks a positive step forward for Citius Oncology, bolstering its financial position and providing the necessary resources to execute its growth strategy. The company anticipates these funds will be instrumental in achieving key developmental and commercial milestones in the near future.
About Citius Oncology, Inc.
Citius Oncology is a late-stage biopharmaceutical company dedicated to developing and commercializing novel oncology therapies. The company’s mission is to address the significant unmet needs of cancer patients by bringing innovative and effective treatment options to market. Citius Oncology’s pipeline includes promising therapeutic candidates that are advancing through clinical development.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and include statements about beliefs and expectations. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “seek,” “should,” “will,” “would” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on the current expectations of Citius Oncology’s management and are subject to risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.
Contact: [Insert Investor Relations Contact Information if available in the original release]
Citius Oncology Announces Closing of $9.0 Million Public Offering
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘Citius Oncology Announces Closing of $9.0 Million Public Offering’ at 2025-07-17 20:30. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.